ES2199981T3 - Modo de preparacion de formulaciones farmaceuticas de particulas finas. - Google Patents

Modo de preparacion de formulaciones farmaceuticas de particulas finas.

Info

Publication number
ES2199981T3
ES2199981T3 ES95909559T ES95909559T ES2199981T3 ES 2199981 T3 ES2199981 T3 ES 2199981T3 ES 95909559 T ES95909559 T ES 95909559T ES 95909559 T ES95909559 T ES 95909559T ES 2199981 T3 ES2199981 T3 ES 2199981T3
Authority
ES
Spain
Prior art keywords
formulation
extrusion
formulations
fine particles
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909559T
Other languages
English (en)
Spanish (es)
Inventor
Jacqueline E. Briskin
Pramod K. Gupta
Claud Loyd
Robert W. Kohler
Susan J. Semla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2199981T3 publication Critical patent/ES2199981T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES95909559T 1994-02-16 1995-02-14 Modo de preparacion de formulaciones farmaceuticas de particulas finas. Expired - Lifetime ES2199981T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19702594A 1994-02-16 1994-02-16
US197025 1998-11-20

Publications (1)

Publication Number Publication Date
ES2199981T3 true ES2199981T3 (es) 2004-03-01

Family

ID=22727703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909559T Expired - Lifetime ES2199981T3 (es) 1994-02-16 1995-02-14 Modo de preparacion de formulaciones farmaceuticas de particulas finas.

Country Status (11)

Country Link
US (1) US6063313A (de)
EP (1) EP0744941B1 (de)
JP (1) JP4040084B2 (de)
AT (1) ATE241962T1 (de)
CA (1) CA2182282C (de)
DE (1) DE69530973T2 (de)
DK (1) DK0744941T3 (de)
ES (1) ES2199981T3 (de)
MX (1) MX9603480A (de)
PT (1) PT744941E (de)
WO (1) WO1995022319A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
ES2325046T3 (es) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible por fusion en caliente.
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DK1073513T3 (da) * 1998-04-24 2003-12-22 Basf Corp Forbedret ekstruderingsproces
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1164872A1 (de) 1999-03-26 2002-01-02 The NutraSweet Company Körnchen aus n-[n-(3,3-dimethylbutyl)-l- g(a)-aspartyl]-l-phenylalanin 1-methyl ester
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE60138876D1 (de) * 2000-03-28 2009-07-16 Sandoz Ag Geschmackmaskierte granulierte teilchen
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024174A2 (en) * 2000-09-22 2002-03-28 Galephar M/F Sustained release composition containing clarithromycin
FR2816507B1 (fr) 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
EP1390383B1 (de) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense-permeationsverstärker
US20030203019A1 (en) * 2002-04-30 2003-10-30 Cornelius John Mark Coated conditioners for use in foods and pharmaceuticals
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2004212976A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-HT agonist formulations
CA2673334C (en) 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
EP2249811A1 (de) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmazeutische dosierform
WO2009137078A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
EP2273983B1 (de) 2008-05-09 2016-07-20 Grünenthal GmbH Verfahren für die zubereitung eines pulverförmigen zwischenprodukts und einer endgültigen festen darreichungsform anhand eines sprüherstarrungsschrittes
PL2456427T3 (pl) 2009-07-22 2015-07-31 Gruenenthal Gmbh Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
EP2516494B1 (de) * 2009-12-23 2016-06-01 Essilor International (Compagnie Générale D'Optique) Verfahren zur umwandlung einer polymerisierbaren zusammensetzung in thermoplastisches polyurethan mit verbesserter vergilbung und anhand dieses verfahrens gewonnener artikel
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EA201401139A1 (ru) 2012-04-18 2015-03-31 Грюненталь Гмбх Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de) 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB757165A (en) * 1953-10-30 1956-09-12 Abbott Lab Compositions of erythromycin for combating bacterial infections
US4374082A (en) * 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
IT1226549B (it) * 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
FR2663818B1 (fr) * 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives

Also Published As

Publication number Publication date
DE69530973T2 (de) 2004-05-19
DE69530973D1 (de) 2003-07-10
ATE241962T1 (de) 2003-06-15
US6063313A (en) 2000-05-16
JP4040084B2 (ja) 2008-01-30
EP0744941A1 (de) 1996-12-04
WO1995022319A1 (en) 1995-08-24
MX9603480A (es) 1997-12-31
EP0744941B1 (de) 2003-06-04
CA2182282A1 (en) 1995-08-24
JPH09509176A (ja) 1997-09-16
CA2182282C (en) 2006-04-18
DK0744941T3 (da) 2003-09-29
PT744941E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
ES2199981T3 (es) Modo de preparacion de formulaciones farmaceuticas de particulas finas.
ES2206592T3 (es) Matriz de liberacion controlada para farmacos.
ES2178876T5 (es) Pastilla de desintegración rápida
EP0142561B1 (de) Langsam wirkende nifedipine-zusammensetzung
CA2065210C (en) Controlled release matrix for pharmaceuticals
US5445829A (en) Extended release pharmaceutical formulations
ES2307653T3 (es) Preparaciones que contienen nateglinida.
ES2717879T3 (es) Formulación de diclofenaco
PT1492511E (pt) Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
PT94898B (pt) Processo para a preparacao de pastilhas medicamentosas de mascar rotogranuladas e cobertas por revestimento para mascarar o sabor
ITMI941410A1 (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPS63166838A (ja) 経口投与用液体製剤
PT85353B (pt) Processo de preparacao de composicoes farmaceuticas de libertacao controlada e de matriz a base de alcool alifatico e resina acrilica
ZA200508361B (en) Orally disintegrating tablets
JP2005527508A5 (de)
JP2007525413A (ja) 味をマスクした有効物質の結晶または顆粒の分散体、分散体を詰めた咀嚼ソフトカプセル、およびその調製方法
KR20010082250A (ko) 약물을 함유하는 구형 미립자의 제조 방법
KR20040004641A (ko) 의약용 조성물
ES2277427T3 (es) Microgranulos de sulfato de morfina, procedimiento de fabricacion y preparaciones farmaceuticas.
JP2006514968A (ja) 低減された苦味を有する製薬組成物
JP5572706B2 (ja) コーティング粒子及びコーティング粒子の製造方法
SK52004A3 (en) Non-steroidal anti-inflammatory formulation comprising a granular composition and an extra-granular composition
ES2288117B1 (es) Composicion farmaceutica solida de gabapentina.
KR20120084296A (ko) 불쾌미 마스킹 입자 및 이것을 함유하는 경구제제
ES2221140T3 (es) Procedimiento para formar composiciones farmaceuticas en pildoras o granulos esfericos de accion controlada y sostenida que contienen bromazepam como agente activo y composiciones farmaceuticas obtenidas por dicho procedimiento.